Journey Medical CorporationDERMNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

defenseworld.net

Financial Review: Zevra Therapeutics (NASDAQ:ZVRA) versus Journey Medical (NASDAQ:DERM)

Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Journey Medical (NASDAQ: DERM - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares Zevra Therapeutics and

globenewswire.com

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that results from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of low-dose oral minocycline (“DFD-29” or commercially known as “Emrosi™) on skin, gastrointestinal (“GI”) and vaginal microflora in healthy adults were published in the Journal of Drugs in Dermatology, a leading peer-reviewed publication in clinical dermatology.

seekingalpha.com

Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript

Journey Medical Corporation ( DERM ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jaclyn Jaffe - Senior Director of Corporate Operations Claude Maraoui - Founder, President, CEO & Director Joseph Benesch - CFO & Corporate Controller Ramsey Alloush - COO, General Counsel & Company Secretary Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Scott Henry - Alliance Global Partners, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Mayank Mamtani - B.

zacks.com

Compared to Estimates, Journey Medical (DERM) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Journey Medical (DERM) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com

Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.12 per share a year ago.

globenewswire.com

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.

globenewswire.com

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET

defenseworld.net

Brighton Jones LLC Lowers Stock Holdings in Journey Medical Corporation $DERM

Brighton Jones LLC trimmed its holdings in shares of Journey Medical Corporation (NASDAQ: DERM) by 26.9% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 16,820 shares of the company's stock after selling 6,200 shares during the period. Brighton Jones LLC owned approximately 0.07% of Journey

defenseworld.net

Focus Partners Advisor Solutions LLC Acquires Shares of 10,000 Journey Medical Corporation $DERM

Focus Partners Advisor Solutions LLC acquired a new stake in Journey Medical Corporation (NASDAQ: DERM) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor acquired 10,000 shares of the company's stock, valued at approximately $72,000. A number of other hedge funds have also modified their holdings

globenewswire.com

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults

globenewswire.com

Journey Medical Corporation to Participate in October 2025 Investor Conferences

SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will participate in two October 2025 investor conferences.

seekingalpha.com

Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon

EMROSI's strong launch is driving Journey Medical's growth, with rapid prescription uptake, expanding prescriber base, and improved payer coverage fueling margin expansion. I see EMROSI as the primary value driver, positioning DERM for sustainable EBITDA profitability by year-end and strong long-term revenue and EPS growth potential. Key risks include Accutane's generic erosion, uncertainty in EMROSI's net revenue per script, and limited cash reserves that may require future capital raises.

zacks.com

New Strong Sell Stocks for September 4th

DERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.

globenewswire.com

Journey Medical Corporation to Participate in September 2025 Investor Conferences

SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences.

globenewswire.com

Journey Medical Corporation to Present at the Emerging Growth Conference

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.

benzinga.com

CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Wednesday.

seekingalpha.com

Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript

Journey Medical Corporation (NASDAQ:DERM ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Claude Maraoui - Founder, President, CEO & Director Jaclyn Jaffe - Senior Director of Corporate Operations Joseph M. Benesch - CFO & Corporate Controller Ramsey Alloush - COO, General Counsel & Company Secretary Conference Call Participants Mayank Mamtani - B.

zacks.com

Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago.

globenewswire.com

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.

zacks.com

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance